105
Participants
Start Date
November 9, 2015
Primary Completion Date
September 22, 2023
Study Completion Date
September 22, 2023
brexucabtagene autoleucel
A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
Cyclophosphamide
Administered intravenously
Fludarabine
Administered intravenously
Axicabtagene Ciloleucel
A single infusion of axicabtagene ciloleucel anti-CD 19 CAR T cells
University of Rochester Medical Center, Rochester
Fox Chase Cancer Center, Philadelphia
Duke University Medical Center, Durham
Winship Cancer Institute of Emory University, Atlanta
University of Miami, Miami
H Lee Moffitt Cancer Center, Tampa
Sarah Cannon Research Institute, Nashville
Vanderbilt University Medical Center, Nashville
Ohio State University, Columbus
Hopital Haut-Leveque, Pessac
Cleveland Clinic Foundation, Cleveland
Barbara Ann Karmanos Cancer Institute, Detroit
Loyola University Chicago, Maywood
University of Chicago, Chicago
Hospital Saint Louis, Paris
Baylor Charles A. Sammons Cancer Center, Dallas
University of Texas MD Anderson Cancer Center, Houston
Sarah Cannon, Denver
Banner MD Anderson, Gilbert
University California Los Angeles (UCLA), Santa Monica
City of Hope, Duarte
Stanford University, Stanford
Universitaetsklinikum Wuerzburg, Würzburg
Robert W. Franz Cancer Research Center, Portland
Swedish Cancer Institute, Seattle
Dana-Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Centre Hospitalier Universitaire (CHU), Bordeaux
Academisch Medisch Centrum, Amsterdam
University Medical Center Groningen, Groningen
Erasmus Medical Center, Rotterdam
Universitätsklinik Dresden, Dresden
Kite, A Gilead Company
INDUSTRY